Advertisement

Safety and efficacy of low-cost alternative urokinase in acute ischemic stroke: A systematic review and meta-analysis

      Highlights

      • Compared to alteplase, urokinase is a less expensive thrombolytic drug with a simpler production and purifying process.
      • Our study found that urokinase is equally safe and effective to alteplase in the treatment of acute ischemic stroke.
      • Urokinase may revolutionize treatment for people suffering from acute ischemic stroke in developing countries.

      Abstract

      Introduction

      Use of intravenous thrombolysis (IVT) for treatment of acute ischemic stroke (AIS) varies greatly between countries, ranging from 10% to 15% in high-income countries to less than 2% in low- and middle income countries (LMICs). This is because alteplase is expensive and has been cited as one of the most common barriers to IVT in LMICs. Urokinase (UK) is a thrombolytic agent which is almost 50 times cheaper with easier production and purification than alteplase. UK may become a cost-effective option for IVT in LMICs if it is found to be safe and effective. We conducted this study to assess the existing evidence on the safety and efficacy of UK vs alteplase for IVT in AIS.

      Methods

      The study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and meta-Analyses) guideline. Systematic literature search was done in PubMed, EMBASE, and Google Scholar for English literature published from 2010 to 2021.

      Results

      A total of 4061 participants in the alteplase and 2062 participants in the UK group were included in the final statistical analysis. After IVT, a good functional outcome at last follow-up was found among 80.57 % of patients in the alteplase group compared to 73.79 % of patients in the UK group (OR: 1.11; 95 % CI: 0.95– 1.31; I2 = 0 %; P = 0.18). Symptomatic Intracerebral Hemorrhage (sICH) was found among 1.77 % of patients in the alteplase group compared to 2.83 % of patients in the UK group (OR: 0.84; 95 % CI: 0.56– 1.26; I2 = 0 %; P = 0.41). Similarly, mortality was found among 5.03 % of patients in the alteplase group compared to 5.42 % of patients in the UK group (OR: 0.87; 95 % CI: 0.66–1.14; I2 = 0 %; P = 0.30).

      Conclusion

      Our meta-analysis found that intravenous UK is not inferior to alteplase in terms of safety and efficacy and can be a viable alternative for IVT in AIS patients in LMICs.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol [Internet]. 2021 Oct 1;20(10):795–820. Available from: https://doi.org/10.1016/S1474-4422(21)00252-0.

      2. Powers WJ. Acute Ischemic Stroke. N Engl J Med [Internet]. 2020 Jul 15;383(3):252–60. Available from: https://doi.org/10.1056/NEJMcp1917030.

        • Zi W.
        • Qiu Z.
        • Li F.
        • Sang H.
        • Wu D.
        • Luo W.
        • et al.
        Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial.
        JAMA. 2021; 325: 234-243
        • Suzuki K.
        • Matsumaru Y.
        • Takeuchi M.
        • Morimoto M.
        • Kanazawa R.
        • Takayama Y.
        • et al.
        Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the SKIP randomized clinical trial.
        JAMA. 2021; 325: 244-253
        • Saini V.
        • Guada L.
        • Yavagal D.R.
        Global epidemiology of stroke and access to acute ischemic stroke interventions.
        Neurology. 2021; 97: S6-S
        • Nepal G.
        • Yadav J.K.
        • Bhandari S.
        • Gautam J.
        • Gajurel B.P.
        Low-cost alternatives for the management of acute ischemic stroke in low and middle-income countries.
        Ann Med Surg [Internet]. 2021; 102969 (Available from:)
        • Bansal V.
        • Roychoudhury P.K.
        Production and purification of urokinase: a comprehensive review.
        Protein Expr Purif. 2006; 45: 1-14
        • Liu L.
        • Chen W.
        • Zhou H.
        • Duan W.
        • Li S.
        • Huo X.
        • et al.
        Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases.
        Stroke Vasc Neurol. 2020; 5: 159-176
        • Kaesmacher J.
        • Bellwald S.
        • Dobrocky T.
        • Meinel T.R.
        • Piechowiak E.I.
        • Goeldlin M.
        • et al.
        Safety and efficacy of intra-arterial urokinase after failed, unsuccessful, or incomplete mechanical thrombectomy in anterior circulation large-vessel occlusion stroke.
        JAMA Neurol. 2020; 77: 318-326
      3. Kaesmacher J, Meinel TR, Kurmann C, Zaidat OO, Castonguay AC, Zaidi SF, et al. Safety and efficacy of intra-arterial fibrinolytics as adjunct to mechanical thrombectomy: a systematic review and meta-analysis of observational data. J Neurointerv Surg [Internet]. 2021 Dec 1;13(12):1073 LP – 1080. Available from: http://jnis.bmj.com/content/13/12/1073.abstract.

        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • Mulrow C.
        • Gøtzsche P.C.
        • Ioannidis J.P.A.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ [Internet]. 2009 Jul; 21 (Available from:)b2700
      4. Bao H, Gao HR, Pan ML, Zhao L, Sun HB. Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction [Internet]. Vol. 29, Technology and Health Care. 2021. p. 85–90. Available from: http://dx.doi.org/10.3233/thc-202382.

        • Wang X.
        • Li X.
        • Xu Y.
        • Li R.
        • Yang Q.
        • Zhao Y.
        • et al.
        Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study.
        Stroke Vasc Neurol. 2021; 6: 603-609
        • Zhang R.
        • Wei H.
        • Ren Y.
        • Wu Y.
        • Luo Y.
        • Zhang L.
        • et al.
        Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China.
        Front Neurol. 2021; 12685454
        • Wang L.
        • Jia C.
        • Zhang Y.
        The comparative study on therapeutic effects of intravenous alteplase thrombolysis, intravenous urokinase thrombolysis and interventional urokinase thrombolysis for acute ischemic stroke.
        Int J Clin Exp Med. 2017; 10: 13646-13652
        • Chen H.
        • Zhu G.
        • Liu N.
        • Zhang W.
        Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke.
        Curr Neurovasc Res. 2014; 11: 62-67
        • Sun F.
        • Liu H.
        • Fu H.X.
        • Zhang S.
        • Qian X.D.
        • Li J.J.
        • et al.
        Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction.
        J Int Med Res. 2020; 48 (300060519895352)
        • Xue Y.
        • Li S.
        • Xiang Y.
        • Wang Z.
        • Wang F.
        • Yu Y.
        • et al.
        Predictors for symptomatic intracranial hemorrhage after intravenous thrombolysis with acute ischemic stroke within 6 h in northern China: a multicenter, retrospective study.
        BMC neurology. 2022; 22: 1-7
      5. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke. Vol. 50, Stroke. United States; 2019. p. e344–418.

        • Adivitiya K.YP.
        The evolution of recombinant thrombolytics: current status and future directions.
        Bioengineered. 2017; 8: 331-358
        • Ogawa A.
        • Mori E.
        • Minematsu K.
        • Taki W.
        • Takahashi A.
        • Nemoto S.
        • et al.
        Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
        Stroke. 2007; 38: 2633-2639
        • Yuan Z.
        • Wang B.
        • Li F.
        • Wang J.
        • Zhi J.
        • Luo E.
        • et al.
        Intravenous thrombolysis guided by a telemedicine consultation system for acute ischaemic stroke patients in China: the protocol of a multicentre historically controlled study.
        BMJ Open. 2015; 5
        • Mori E.
        • Tabuchi M.
        • Yoshida T.
        • Yamadori A.
        Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.
        Stroke. 1988; 19: 802-812
        • del Zoppo G.J.
        • Higashida R.T.
        • Furlan A.J.
        • Pessin M.S.
        • Rowley H.A.
        • Gent M.
        PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
        Stroke. 1998; 29: 4-11
      6. Nepal G, Yadav JK, Basnet B, Shrestha TM, Kharel G, Ojha R. Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal. BMC Neurol [Internet]. 2019;19(1):155. Available from: https://doi.org/10.1186/s12883-019-1378-3.

        • Diaz A.
        • Merino P.
        • McCann P.
        • Yepes M.A.
        • Quiceno L.G.
        • Torre E.
        • et al.
        Urokinase-type plasminogen activator promotes N-cadherin-mediated synaptic recovery in the ischemic brain.
        J Cereb Blood Flow Metab. 2021; 41: 2381-2394
        • Kadir R.R.A.
        • Bayraktutan U.
        Urokinase plasminogen activator: a potential thrombolytic agent for ischaemic stroke.
        Cell Mol Neurobiol. 2020; 40: 347-355
        • Berkowitz A.L.
        • Mittal M.K.
        • Mclane H.C.
        • Shen G.C.
        • Muralidharan R.
        • Lyons J.L.
        • et al.
        Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke.
        Int J Stroke. 2014; 9: 349-355
        • Khatib R.
        • Arevalo Y.A.
        • Berendsen M.A.
        • Prabhakaran S.
        • Huffman M.D.
        Presentation, evaluation, management, and outcomes of acute stroke in low- and middle-income countries: a systematic review and meta-analysis.
        Neuroepidemiology. 2018; 51: 104-112
        • Feigin V.L.
        • Lawes C.M.M.
        • Bennett D.A.
        • Barker-Collo S.L.
        • Parag V.
        Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review.
        Lancet Neurol. 2009; 8: 355-369
        • Al Khathaami A.M.
        • Al Bdah B.
        • Tarawneh M.
        • Alskaini M.
        • Alotaibi F.
        • Alshalan A.
        • et al.
        Utilization of intravenous tissue plasminogen activator and reasons for nonuse in acute ischemic stroke in saudi Arabia.
        J Stroke Cerebrovasc Dis. 2020; 29
      7. Abanto C, Valencia A, Calle P, Barrientos D, Flores N, Novoa M, et al. Challenges of Thrombolysis in a Developing Country: Characteristics and Outcomes in Peru. J Stroke Cerebrovasc Dis. 2020 Jul;29(7).

        • William A.
        • Pannu A.
        • Kate M.
        • Jaison V.
        • Gupta L.
        • Bose S.
        • et al.
        Quality indicators of intravenous thrombolysis from North India.
        Ann Indian Acad Neurol. 2017; 20: 393-398
        • de Souza A.C.
        • Sebastian I.A.
        • Zaidi W.A.W.
        • Nasreldein A.
        • Bazadona D.
        • Amaya P.
        • et al.
        Regional and national differences in stroke thrombolysis use and disparities in pricing, treatment availability, and coverage.
        Int J Stroke. 2022; (174749302210824)
        • Pandian J.D.
        • Padma V.
        • Vijaya P.
        • Sylaja P.N.
        • Murthy J.M.K.
        Stroke and thrombolysis in developing countries.
        Int J Stroke. 2007; 2: 17-26
        • Mehndiratta M.M.
        • Singhal A.B.
        • Chaturvedi S.
        • Sivakumar M.R.
        • Moonis M.
        Meeting the challenges of stroke in India.
        Neurology. 2013; 80: 2246-2247
        • Cui W.
        • Liu R.
        • Jin H.
        • Lv P.
        • Sun Y.
        • Men X.
        • et al.
        pH gradient difference around ischemic brain tissue can serve as a trigger for delivering polyethylene glycol-conjugated urokinase nanogels.
        J Control release Off J Control Release Soc. 2016; 225: 53-63